Last Updated : February 4, 2025
Details
FilesGeneric Name:
belantamab mafodotin, bortezomib, dexamethasone
Project Status:
Active
Therapeutic Area:
Previously treated multiple myeloma
Manufacturer:
GlaxoSmithKline Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
PC0379-000
Call for patient/clinician input closed:
Tumour Type:
Myeloma
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Belantamab mafodotin is indicated for the treatment of multiple myeloma in combination with bortezomib and dexamethasone (BVd) in adult patients who have received at least one prior therapy.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Belantamab mafodotin is indicated for the treatment of multiple myeloma in combination with bortezomib and dexamethasone (BVd) in adult patients who have received at least one prior therapy.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | August 07, 2024 |
|---|---|
| Call for patient/clinician input closed | November 07, 2024 |
| Submission received | December 19, 2024 |
| Submission accepted | January 10, 2025 |
| Review initiated | January 13, 2025 |
| Draft CADTH review report(s) provided to sponsor for comment | April 09, 2025 |
| Deadline for sponsors comments | April 22, 2025 |
| CADTH review report(s) and responses to comments provided to sponsor | May 30, 2025 |
| Expert committee meeting (initial) | June 11, 2025 |
| Draft recommendation issued to sponsor | - |
| Draft recommendation posted for stakeholder feedback | - |
| End of feedback period | - |
Files
Last Updated : February 4, 2025